GRAL - CIK 0001699031
GRAIL, LLC trades as GRAL and has a market capitalization of $2.55 B, making it the #1931 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $147.17M, up 17.2% from the prior year and net income of -$408.35M. This page tracks GRAIL, LLC through 228 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -9719.3% to -277.5% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-05 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| Insider trade | 4 | 2026-04-17 |
| Insider trade | 4 | 2026-04-17 |
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia | GRAIL, Inc.
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares | GRAIL, Inc.
The largest companies sharing GRAIL, LLC's SEC industry classification (services-medical laboratories).
GRAIL, LLC (GRAL) has a market capitalization of $2.55 B as of 2026-06-10, ranking #1931 among US-listed companies.
GRAIL, LLC reported revenue of $147.17M for fiscal year 2025, an increase of 17.2% year over year.
In its latest fiscal year GRAIL, LLC reported a net loss of $408.35M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.